NxStage Medical Inc. (NASDAQ:NXTM) reached a new 52-week high on Friday . The stock traded as high as $23.08 and last traded at $22.77, with a volume of 321,092 shares traded. The stock had previously closed at $21.84.

NXTM has been the topic of several analyst reports. Piper Jaffray Cos. reiterated a “buy” rating and issued a $21.00 target price on shares of NxStage Medical in a report on Friday, June 3rd. Northland Securities upgraded shares of NxStage Medical from a “market perform” rating to an “outperform” rating and set a $25.00 target price on the stock in a report on Tuesday, June 28th. Wells Fargo & Co. reiterated a “sell” rating on shares of NxStage Medical in a report on Thursday, May 5th. BTIG Research reiterated a “buy” rating and issued a $27.00 target price on shares of NxStage Medical in a report on Tuesday, June 7th. Finally, Canaccord Genuity reiterated a “buy” rating on shares of NxStage Medical in a report on Wednesday, May 4th. One equities research analyst has rated the stock with a sell rating and seven have issued a buy rating to the company. NxStage Medical presently has a consensus rating of “Buy” and an average target price of $24.50.

The company has a 50 day moving average price of $20.11 and a 200 day moving average price of $17.72. The company’s market cap is $1.48 billion.

NxStage Medical (NASDAQ:NXTM) last announced its quarterly earnings results on Wednesday, May 4th. The medical device company reported ($0.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.05) by $0.03. During the same period last year, the firm posted ($0.09) earnings per share. The company had revenue of $89.20 million for the quarter, compared to the consensus estimate of $88.40 million. The company’s revenue for the quarter was up 12.2% compared to the same quarter last year. Equities research analysts predict that NxStage Medical Inc. will post ($0.12) EPS for the current year.

In other NxStage Medical news, President Joseph E. Turk, Jr. sold 1,500 shares of the business’s stock in a transaction that occurred on Thursday, May 12th. The shares were sold at an average price of $17.89, for a total transaction of $26,835.00. Following the sale, the president now directly owns 103,280 shares of the company’s stock, valued at approximately $1,847,679.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, President Joseph E. Turk, Jr. sold 2,000 shares of the business’s stock in a transaction that occurred on Thursday, April 21st. The stock was sold at an average price of $15.73, for a total transaction of $31,460.00. Following the sale, the president now directly owns 104,780 shares in the company, valued at $1,648,189.40. The disclosure for this sale can be found here.

A number of large investors have bought and sold shares of NXTM. Morgan Stanley raised its stake in NxStage Medical by 1.3% in the fourth quarter. Morgan Stanley now owns 67,174 shares of the medical device company’s stock worth $1,472,000 after buying an additional 874 shares during the last quarter. California State Teachers Retirement System raised its stake in NxStage Medical by 1.6% in the fourth quarter. California State Teachers Retirement System now owns 117,165 shares of the medical device company’s stock worth $2,567,000 after buying an additional 1,869 shares during the last quarter. New York State Common Retirement Fund raised its stake in NxStage Medical by 4.1% in the fourth quarter. New York State Common Retirement Fund now owns 76,493 shares of the medical device company’s stock worth $1,676,000 after buying an additional 3,000 shares during the last quarter. State Board of Administration of Florida Retirement System raised its stake in NxStage Medical by 9.0% in the fourth quarter. State Board of Administration of Florida Retirement System now owns 53,686 shares of the medical device company’s stock worth $1,176,000 after buying an additional 4,450 shares during the last quarter. Finally, Rhumbline Advisers raised its stake in NxStage Medical by 8.3% in the fourth quarter. Rhumbline Advisers now owns 68,426 shares of the medical device company’s stock worth $1,499,000 after buying an additional 5,240 shares during the last quarter.

NxStage Medical, Inc is a medical device company. The Company is engaged in the development, manufacturing and marketing of products for the treatment of kidney failure, fluid overload and related blood treatments and procedures. The Company’s products include the System One, Streamline Blood Tubing Sets and AV Fistula and Apheresis Needles.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.